Develops CRISPR-based medicines and gene-edited cell therapies for people with blood disorders, cardiovascular disease and other serious conditions.
10-K for FY2025, filed Feb 12, 2026Our mission is to create transformative gene-based medicines for serious human diseases. We are a leading biopharmaceutical company focused…View ↗
We have established a portfolio of therapeutic programs spanning four core franchises: hemoglobinopathies, in vivo, CAR T approaches and…View ↗
Hemoglobinopathies: Our most advanced program, CASGEVY, has received approval in the United States and other countries for the treatment of…View ↗
In vivo approaches: We are advancing a portfolio of programs leveraging in vivo editing for both common and rare diseases, as well as using…View ↗
CAR T: We are progressing next-generation gene-edited cell therapy programs, including allogeneic chimeric antigen receptor T cell, or CAR…View ↗
Regenerative medicine: We are advancing a deviceless beta cell replacement product candidate consisting of unencapsulated precursor islet…View ↗
10-K for FY2025, filed Feb 12, 2026
FY2025 revenue by product or service ↗$3.5M
10-K for FY2025, filed Feb 12, 2026
$3.5M ↗| Segment | Share | Revenue |
|---|---|---|
|
Collaboration Revenue
|
0.0%
FY2022: 36%
|
Collaboration Revenue, FY2025
$0 Sources
|
|
Grant Revenue
|
100%
FY2022: 64%
|
Grant Revenue, FY2025
$3.5M Sources
|
No. It lost $581.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 2, 2026
−$111.4MView ↗
10-Q for Q3 FY2026, filed Nov 2, 2026
Open tableView ↗
Shrinking. Revenue fell 100% in 4 years, from $915M in FY2021 to $3.5M in FY2025, about 75% a year.
CAR T adds autoimmune trials
The older report outlines CAR T programs for cancer; the latest report also describes trials for autoimmune diseases alongside oncology programs.
10-K for FY2022, filed Feb 21, 2023 10-K for FY2025, filed Feb 12, 2026
Diabetes cell therapy takes a different form
The older report described ViaCyte-linked, gene-edited stem-cell candidates for diabetes; the latest describes a beta-cell replacement candidate made from precursor islet cells and says it licensed gene-editing intellectual property to Vertex.
10-K for FY2022, filed Feb 21, 2023 10-K for FY2025, filed Feb 12, 2026We continue to advance our regenerative medicine portfolio, including in diabetes. We are advancing CTX213, a deviceless beta cell…View ↗
Competes with Editas Medicine, Intellia Therapeutics, Metagenomi, Scribe Therapeutics, Beam Therapeutics, Prime Medicine, Tessera Therapeutics, Verve Therapeutics, Allogene Therapeutics, Cellectis, Iovance Biotherapeutics, Factor Bioscience, Korro Bio, nChroma Bio, Precision BioSciences, Sangamo Therapeutics, Tune Therapeutics, Wave Life Sciences, Sarepta Therapeutics, and Alnylam
10-K for FY2025, filed Feb 12, 2026Our platform and product focus is on the development of therapies using CRISPR/Cas gene editing technology. We are aware of several…View ↗
Loading...